ArticleJTO clinical and research reports2026
Efficacy of Adding Immune Checkpoint Inhibition to Chemotherapy, With or Without VEGF Inhibition, in Patients With Advanced
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Whether adding immunotherapy to chemotherapy is beneficial for some patients with Methods: We performed a systematic review and meta-analysis with reconstructed individual patient data to assess outcomes to chemo-immunotherapy with or without VEGFi in patients with advanced Results: Among seven randomized clinical trials (n = 2196 patients), compared with chemotherapy with or without VEGFi, chemo-immunotherapy extended the median progression-free survival whether combined with VEGFi (8.1 versus 5.5 mo; hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.53-0.67; Conclusion: Chemo-immunotherapy with or without VEGFi may produce a modest survival improvement in select patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.